More than 30% of adults worldwide have experienced generalized anxiety disorder and 5% suffer from depression, not including the population with other mental illnesses such as attention deficit hyperactivity disorder (ADHD) or post-traumatic stress disorder (PTSD).

Based on statistics, the estimated revenue of the U.S. mental health market was $397.4 billion and the global market size is expected to grow to more than $500 billion by 2030.
The market growth has brought about the rise of novel treatments. Psychedelics, a family of highly controversial drugs, are being gradually destigmatized and attracting attention from scientists and investors. What are the most common psychedelics?